Drug Profile
Research programme: neurogenesis therapeutics - Newron Sweden
Alternative Names: sNN 0126; sNN 0465Latest Information Update: 13 Sep 2013
Price :
$50
*
At a glance
- Originator NeuroNova AB
- Developer Newron Sweden AB
- Class Nerve growth factors; Peptides; Proteins; Small molecules
- Mechanism of Action Neuron stimulants; Neuropilin-1 inhibitors; Platelet-derived growth factor receptor agonists; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Amyotrophic lateral sclerosis; Huntington's disease; Major depressive disorder; Neurological disorders; Parkinson's disease
Most Recent Events
- 13 Sep 2013 Discontinued - Preclinical for Alzheimer's disease in Sweden (unspecified route)
- 13 Sep 2013 Discontinued - Preclinical for Amyotrophic lateral sclerosis in Sweden (Intracerebro-ventricular)
- 13 Sep 2013 Discontinued - Preclinical for Huntington's disease in Sweden (unspecified route)